scholarly journals Honokiol Alleviates Hypertrophic Scar by Targeting Transforming Growth Factor-β/Smad2/3 Signaling Pathway

2017 ◽  
Vol 8 ◽  
Author(s):  
Danyang Zhao ◽  
Yu Wang ◽  
Chao Du ◽  
Shengzhou Shan ◽  
Yifan Zhang ◽  
...  
Keyword(s):  
Growth Factor ◽  
Signaling Pathway ◽  
Hypertrophic Scar ◽  
Transforming Growth Factor ◽  
Transforming Growth Factor Β

scholarly journals Genetic variation in the transforming growth factor-β signaling pathway and survival after diagnosis with colon and rectal cancer

Cancer ◽  
2011 ◽  
Vol 117 (18) ◽  
pp. 4175-4183 ◽  
Author(s):  
Martha L. Slattery ◽  
Abbie Lundgreen ◽  
Jennifer S. Herrick ◽  
Roger K. Wolff ◽  
Bette J. Caan
Keyword(s):  
Rectal Cancer ◽  
Genetic Variation ◽  
Growth Factor ◽  
Signaling Pathway ◽  
Transforming Growth Factor ◽  
Transforming Growth Factor Β ◽  
Colon And Rectal Cancer

Expression analysis of selected miR‐206 targets from the transforming growth factor‐β signaling pathway in breast cancer

2019 ◽  
Vol 120 (8) ◽  
pp. 13545-13553
Author(s):  
Mahnaz Seifi‐Alan ◽  
Ali Dianatpour ◽  
Lobat Geranpayeh ◽  
Reza Mirfakhraie ◽  
Mir D. Omrani ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Signaling Pathway ◽  
Expression Analysis ◽  
Transforming Growth Factor ◽  
Transforming Growth Factor Β

scholarly journals Transforming Growth Factor-Beta (TGFβ) Signaling Pathway in Cholangiocarcinoma

Cells ◽  
2019 ◽  
Vol 8 (9) ◽  
pp. 960 ◽  
Author(s):  
Panagiotis Papoutsoglou ◽  
Corentin Louis ◽  
Cédric Coulouarn
Keyword(s):  
Growth Factor ◽  
Signaling Pathway ◽  
Transforming Growth Factor Beta ◽  
Transforming Growth Factor ◽  
Transforming Growth Factor Β ◽  
Tgfβ Signaling ◽  
Efficient Treatment ◽  
Tumor Onset ◽  
Tgfβ Signaling Pathway

Cholangiocarcinoma is a deadly cancer worldwide, associated with a poor prognosis and limited therapeutic options. Although cholangiocarcinoma accounts for less than 15% of liver primary cancer, its silent nature restricts early diagnosis and prevents efficient treatment. Therefore, it is of clinical relevance to better understand the molecular basis of cholangiocarcinoma, including the signaling pathways that contribute to tumor onset and progression. In this review, we discuss the genetic, molecular, and environmental factors that promote cholangiocarcinoma, emphasizing the role of the transforming growth factor β (TGFβ) signaling pathway in the progression of this cancer. We provide an overview of the physiological functions of TGFβ signaling in preserving liver homeostasis and describe how advanced cholangiocarcinoma benefits from the tumor-promoting effects of TGFβ. Moreover, we report the importance of noncoding RNAs as effector molecules downstream of TGFβ during cholangiocarcinoma progression, and conclude by highlighting the need for identifying novel and clinically relevant biomarkers for a better management of patients with cholangiocarcinoma.

Transforming growth factor β signaling pathway: A promising therapeutic target for cancer

2019 ◽  
Vol 235 (3) ◽  
pp. 1903-1914 ◽  
Author(s):  
Yuhong Chen ◽  
Cuixia Di ◽  
Xuetian Zhang ◽  
Jing Wang ◽  
Fang Wang ◽  
...  
Keyword(s):  
Growth Factor ◽  
Signaling Pathway ◽  
Therapeutic Target ◽  
Transforming Growth Factor ◽  
Transforming Growth Factor Β ◽  
Promising Therapeutic Target
Sign in / Sign up

Export Citation Format

Share Document